FRACTYL HEALTH, INC. - 8-K Filing
Fractyl Health reported Q1 2026 financial results with a net income of $9.2 million, compared to a net loss of $23.7 million in the same period last year, driven by a non-cash accounting change related to warrant liabilities. The company reiterated key Revita clinical milestones including early Q4 2026 data readouts and potential FDA De Novo submission for post-GLP-1 weight maintenance. Rejuva's lead gene therapy candidate RJVA-001 received CTA authorization in the Netherlands, with first-in-human dosing expected in H2 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $GUTS